Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMGMCI: M-guard in Mild Cognitive Impairment
jRCTs031220284Recruiting
- Sponsor
- Glovia
- Start
- Dec 2022
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial in Mild Cognitive Impairment (MCI) comparing M-guard with Placebo (2 arms). Primary endpoint: iADRS. Started Dec 2022; status: recruiting.
02
Drugs
M-Guard
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on jRCTs031220284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220284.